Literature DB >> 27879540

Severe Hemolytic Anemia Following Intravenous Immunoglobulin in an Infant With Kawasaki Disease.

Vlad Tocan1, Akari Inaba, Tamami Kurano, Motoshi Sonoda, Keiji Soebijanto, Hideki Nakayama.   

Abstract

Severe hemolytic anemia (HA) is an uncommon adverse reaction of intravenous immunoglobulin (IVIg) administration. Previous reports assume that antibodies contained in IVIg preparations are the cause of hemolysis. We report a 10-month-old infant with Kawasaki disease who was treated with high-dose IVIg and developed severe HA. The patient's Rh blood type was D+C+c+E-e+. He developed anti-C and anti-e antibodies following treatment with IVIg, and, after considering all possible causes of hemolysis, we concluded that this was a case of autoimmune HA induced by immunoglobulin treatment. The hyperinflammatory condition associated with Kawasaki disease may have contributed to the severity of anemia.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27879540     DOI: 10.1097/MPH.0000000000000704

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  1 in total

Review 1.  Incidence and risk factors for intravenous immunoglobulin-related hemolysis: A systematic review of clinical trial and real-world populations.

Authors:  Hillary Cuesta; Ibrahim El Menyawi; Alphonse Hubsch; Liane Hoefferer; Orell Mielke; Susie Gabriel; Amgad Shebl
Journal:  Transfusion       Date:  2022-08-02       Impact factor: 3.337

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.